Zevra Therapeutics, Inc. (NASDAQ:ZVRA) SVP Timothy J. Sangiovanni Sells 3,000 Shares of Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) SVP Timothy J. Sangiovanni sold 3,000 shares of Zevra Therapeutics stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $23,580.00. Following the transaction, the senior vice president now directly owns 16,341 shares of the company’s stock, valued at approximately $128,440.26. This represents a 15.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Zevra Therapeutics Price Performance

Zevra Therapeutics stock opened at $8.07 on Friday. The firm has a 50-day moving average of $8.22 and a two-hundred day moving average of $8.04. Zevra Therapeutics, Inc. has a 1 year low of $4.20 and a 1 year high of $9.76. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.25). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The business had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $5.04 million. During the same period in the previous year, the company posted ($0.40) EPS. Equities analysts anticipate that Zevra Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Canaccord Genuity Group dropped their price target on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Zevra Therapeutics in a research note on Wednesday, November 20th. Finally, Cantor Fitzgerald raised shares of Zevra Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 29th. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $21.57.

Institutional Investors Weigh In On Zevra Therapeutics

Hedge funds have recently modified their holdings of the business. Vestal Point Capital LP purchased a new stake in shares of Zevra Therapeutics in the 3rd quarter worth approximately $3,644,000. Sanctuary Advisors LLC bought a new position in shares of Zevra Therapeutics during the 2nd quarter worth approximately $474,000. Geode Capital Management LLC raised its stake in shares of Zevra Therapeutics by 14.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock worth $7,246,000 after acquiring an additional 129,600 shares in the last quarter. Barclays PLC raised its stake in shares of Zevra Therapeutics by 292.6% during the 3rd quarter. Barclays PLC now owns 57,599 shares of the company’s stock worth $399,000 after acquiring an additional 42,926 shares in the last quarter. Finally, Propel Bio Management LLC bought a new position in shares of Zevra Therapeutics during the 3rd quarter worth approximately $1,248,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.